.

The Quarterly Dose

An Overview of the Protections Afforded by the Peer Review Protection Act

The Quarterly Dose – November 2025

November 1, 2025

by Sandrine Gibbons

As scientific and medical advancements have accelerated, so has the complexity of medical decision-making, exposing a need for standardization in the United States. In 1952, the Joint Commission created the mandatory clinical peer review process. Often referred to as “medical peer review,” it is the process by which health care providers establish and maintain reliable standards of quality in patient care.

Clinical peer review entails periodic meetings of professional health care providers to evaluate the quality and efficiency of the services performed by other professional health care providers within the same hospital or health system. Today, countries with reputations for the most exceptional health care all mandate clinical peer review processes. In the United States, the clinical peer review process is so trusted to maintain and improve the quality of health care that every state has enacted a statute preventing certain information and documents discussed in peer review meetings from disclosure in litigation.

In 1974, the Pennsylvania legislature enacted the Peer Review Protection Act (PRPA) to provide an evidentiary privilege to protect the “proceedings and documents of a review committee,” conducting peer review activities by professional health care providers, in conformity with its provisions. Reginelli v. Boggs, 181 A.3d 293, 296 (Pa. 2018). The PRPA’s evidentiary privilege is set forth in Section 425.4:

The proceedings and records of a review committee shall be held in confidence and shall not be subject to discovery or introduction into evidence in any civil action against a professional health care provider arising out of the matters which are the subject of evaluation and review by such committee and no person who was in attendance at a meeting of such committee shall be permitted or required to testify in any such civil action as to any evidence or other matters produced or presented during the proceedings of such committee or as to any findings, recommendations, evaluations, opinions or other actions of such committee or any members thereof.

Between 2018 and 2021, courts both narrowed and broadened the application of this privilege.

Narrowing: Only “Peer Review Committees” Can Assert the Privilege
In Reginelli v. Boggs, the Pennsylvania Supreme Court held the defendants were not entitled to this privilege primarily because the physician’s employer was not a “professional health care provider” covered under the PRPA. UPMC Emergency Medicine, Inc. (ERMI) staffed the physician to Monongahela Valley Hospital (MVH) and was therefore the physician’s employer. The court held ERMI was not a “professional health care provider” because it was not regulated and licensed to practice medicine. The PRPA defines the term “professional health care providers” as “individuals or organizations who are approved, licensed or otherwise regulated to practice or operate in the health care field under the laws of the Commonwealth.” Because the PRPA’s language explicitly states the “individual or organization be `approved, licensed or otherwise regulated to practice or operate in the health care field under the laws of the Commonwealth- to benefit from the privilege—and the employer at issue was not—the court found the PRPA privilege did not apply.

Furthermore, the court found each of the defendants could only be construed as mere “review organizations” that engaged only in a process of reviewing professional qualifications credentialing). Therefore, they were not “review committees” under the PRPA. The PRPA defines a “review organization” as “any committee engaging in peer review....” Although the language of Section 425.4 suggests it pertains to review organizations, the substantive text sets forth confidentiality mandates and testimonial privileges relating to the work and records of review committees. Since the PRPA privilege does not explicitly extend to any review organization that merely conducts credentialing review, the defendants did not qualify for the privilege. Here, the court determined that MVH’s physician merely reviewed the credentials of hospital staff and did not engage in review of the quality and efficiency of the services staff performed.

Narrowing: Credentialing Files are Not Protected
In Estate of Krappa v. Lyons, the Pennsylvania Superior Court interpreted the PRPA and Reginelli to mean a credentialing file will not be entitled to the PRPA’s evidentiary privilege if it (1) consists entirely of credentialing materials, and (2) was maintained by the hospital’s “credentialing committee.” In Krappa, a patient’s estate brought suit alleging a delay in diagnosis after the patient had died of cancer. During discovery, the estate sought unredacted copies of the medical center’s files concerning two physicians who treated the patient. As discussed in Reginelli, the Superior Court determined credentialing files generated and maintained by a hospital’s credentialing committee are not protected under the PRPA because a credentialing committee does not qualify as a “review committee” engaging in peer review.

Narrowing: Event Reports, Root-Cause Analyses are Not Protected
In Ungurian v. Beyzman, the Pennsylvania Superior Court articulated that the PRPA privilege does not encompass event reports and root-cause analyses where there is no indication those documents were generated “exclusively for a PRPA 'review committee.' This was a case where the patient’s mother brought a medical malpractice action against physicians, hospital staff, clinics, corporations, and the hospital itself alleging their collective negligence caused the total and permanent incapacity of her child who had undergone a cystoscopy at the hospital. The mother-plaintiff sought to compel various documents, including event reports and root cause analysis, and the defendants appealed arguing protections pursuant to the federal Patient Safety and Quality Improvement Act of 2005 and PRPA. Consistent with the Superior Court’s reasoning in Lyons, the court reasoned that, because neither event reports nor root-cause analyses were generated in the course of peer review and merely constituted business records of the hospital, these documents were not entitled to the privilege.

Broadening: Privilege Extends to Peer Review as a Function, not just a “Peer Review Committee”
In Leadbitter v. Keystone Anesthesia Consultants, Ltd., the Pennsylvania Supreme Court expanded the potential applicability of the PRPA’s evidentiary privilege in contrast to its opinion in Reginelli where, consistent with the plain language of § 425.3-425.4, the court found the title or name of the body conducting the review was determinative of whether the privilege would apply. Here, however, the Leadbitter court articulated that it is instead the actual function or “activity” of a review organization/committee which determines whether the privilege applies. In this case, a physician applied to be appointed to the medical staff of St. Clair Hospital and for orthopedic surgery clinical privileges. After performing surgery on a patient, the patient suffered a series of strokes and filed a medical malpractice suit against the hospital, seeking that they produce documents relating to the physician’s credentials, as they claimed the physician lacked expertise.

The hospital denied the requests, arguing the PRPA privilege applied because the work of their credentials committee was multifaceted and included peer review. Specifically, the hospital argued that this work included both privileging and credentialing and that, because privileging is covered by the PRPA as a peer review activity, the hospital was entitled to statutory protection. It pointed out—and the Leadbitter court acknowledged—that Reginelli’s reasoning was limited to credentialing review for purposes of appointment to a hospital’s medical staff. The Leadbitter court agreed that privileging is distinct from credentialing as it involves giving the physician permission to treat patients at the hospital, and not merely to exercise political rights in relation to staff and committee meetings. As such, it agreed with the proposition that a credentials committee is entitled to the PRPA’s protections to the extent it performs a peer-review function—in this case, privileging. In short, because of Leadbitter, the PRPA’s evidentiary privilege extends to those who engage in “peer review activities” as the actual function of the committee—not the title—determines whether the privilege applies.

Narrowing: Private Physician Practice Groups Cannot Assert the Privilege
In 2021, the Eastern District considered whether a report authored by a radiologist who reviewed care provided at a hospital was protected under PRPA. In Lasheena Sipp Lipscob v. Einstein Physicians Pennypack Pediatrics, the plaintiff sued both a hospital and a private radiology practice that provided radiology services to the hospital, arguing the defendants failed to diagnose testicular torsion resulting in the loss of a testicle. A report generated by a radiologist employed by the practice was identified in discovery which reviewed the quality of care rendered to the plaintiff’s minor-patient. The defendants argued this report was protected under the PRPA because it was created for a “peer review purpose.” The court disagreed, reasoning first that the radiology group (i.e., a private medical practice) was not a “professional healthcare provider” within the meaning of the PRPA and therefore not eligible for the evidentiary privilege. The Pennsylvania Superior Court ruled consistent with this conclusion in 2021 in the non-precedential decision of Bousamra v. Excela Health.

Second, while the hospital defendant was clearly a “professional health care provider” under the PRPA, it too could not assert the evidentiary privilege over this report because the authoring radiologist did not generate the report as part of any hospital “committee” as contemplated under the Act. In other words, because the report was not generated for or provided to any hospital “committee” performing a “peer review function,” the PRPA privilege was not extended.

Key Takeaways
In enacting the Peer Review Protection Act, the Pennsylvania legislature recognized that candid and rigorous clinical peer review is essential to upholding the quality of patient care. Accordingly, the evolving body of case law interpreting the PRPA’s evidentiary privilege carries substantial implications for health care providers and institutions, particularly in the context of medical malpractice litigation. To preserve the confidentiality afforded by the PRPA, documents assessing the quality of care should be created by or for a hospital committee engaged in peer review functions, such as privileging. As with any legal privilege, the integrity of protection depends on strict adherence to confidentiality—such materials must not be disclosed to unauthorized parties, whether internal or external to the institution. 


The Quarterly Dose – November 2025, has been prepared for our readers by Marshall Dennehey. It is solely intended to provide information on recent legal developments and is not intended to provide legal advice for a specific situation or to create an attorney-client relationship. We welcome the opportunity to provide such legal assistance as you require on this and other subjects. If you receive the alerts in error, please send a note to tamontemuro@mdwcg.com. ATTORNEY ADVERTISING pursuant to New York RPC 7.1. © 2025 Marshall Dennehey. All Rights Reserved.

Firm Highlights

Result

No-Cause Jury Verdict Secured in Wrongful Death Trial

We successfully obtained a no-cause jury verdict in a 13-day wrongful death trial. The decedent, a 59-year-old man, was admitted to the emergency room on February 15, 2019, with complaints of abdominal pain, decreased appetite, and constipation, despite the use of laxatives. The patient did not complain of any nausea, vomiting, or diarrhea. He had a significant medical history including diabetes, hypertension, prior coronary artery stenting, morbid obesity (with past gastric bypass surgery), longstanding ventral hernia, and back pain. A CT scan revealed multiple hernias and a potential closed-loop bowel obstruction, leading to a surgery consultation. Our client, an emergency general surgeon, interpreted that the patient did not have a closed loop or any significant obstruction and recommended non-surgical management. The patient was approved to have clear liquids, and had a vomiting incident shortly after, but our client was not notified. The patient was returned to NPO status, and after improving overnight, he was returned to “clears” and additional medical and renal consults were ordered. Our client did not receive any communications from the residents/nurses of any changes in the patient’s condition. On February 18, 2019, two rapid responses were called due to increased heart rate and vomiting. It is believed that the vomiting resulted in aspiration, causing sepsis, ultimately leading to the patient’s death. During the trial, the plaintiff’s sole medical expert highlighted imaging on the wrong hernia, which called into question all of his opinions in the case. We made key objections related to the expert testimony, limiting what the allegations were, and preventing new allegations from being made. After approximately two and a half hours of deliberating, the jury returned a no-cause verdict. 

Thought Leadership

SIU Gets a Boost: NJ Supreme Court Affirms Insurers' Right to Litigate, Not Arbitrate, Fraud Claims

In a significant win for insurers' Special Investigation Units, the New Jersey Supreme Court clarified that statutory insurance fraud and racketeering claims may proceed in court rather than through PIP arbitration. At issue was whether insurance fraud claims brought under New Jersey's Insurance Fraud Prevention Act (IFPA) and the state's Anti-Racketeering Act (NJ RICO) are subject to mandatory arbitration under the Automobile Insurance Cost Reduction Act’s (AICRA) PIP dispute-resolution framework. Allstate had sued a network of medical practices, physicians, and related corporate entities, alleging a scheme to extract more than $1.7 million in PIP benefits through fraudulent and misleading billing. The trial court dismissed Allstate's complaint and compelled arbitration, reading AICRA's arbitration clause — which covers "any dispute regarding the recovery of... benefits" under PIP coverage, N.J.S.A. 39:6A-5.1(a) — as sweeping in fraud and racketeering claims along with routine benefit disputes. The Supreme Court affirmed the Appellate Division's reversal, adopting Judge Gilson's opinion below (480 N.J. Super. 566 (App. Div. 2025)) as its own reasoning. The Court held that IFPA and RICO claims fall outside the scope of AICRA's PIP arbitration mechanism because that "streamlined and specialized" process cannot grant the relief those statutes contemplate — treble damages, injunctive relief, broad discovery, and joinder of third parties — and because arbitrators lack authority to award compensatory or treble damages to an insurer. The Court also rejected the argument that Allstate's own Decision Point Review Plans independently compel arbitration, finding those plan provisions no broader than AICRA's own arbitration clause. Notably, the Court expressly disagreed with the Third Circuit's contrary holding in GEICO v. Mt. Prospect Chiropractic Center, 98 F.4th 463 (3d Cir. 2024), concluding it is not bound by that federal interpretation of New Jersey law. Insurers retain the right to pursue IFPA and RICO claims in the Law Division, with a jury trial. For SIU units and NJ insurance carriers, this decision is a significant win: it forecloses defense clinics' primary procedural tool for shunting fraud investigations into limited-scope PIP arbitration, where treble damages, RICO relief, and meaningful discovery were never realistically available. Carriers building cases against fraudulently structured clinics, straw-owned practices, or coordinated billing networks can now proceed with confidence that a well-pleaded IFPA/RICO complaint stays in the Law Division rather than being diverted to arbitration on a motion to compel. Practically, this strengthens SIU's leverage in settlement negotiations, preserves civil discovery tools (subpoenas, depositions, joinder of related corporate entities) critical to unwinding complex ownership and referral schemes, and resolves the split with the Third Circuit in favor of NJ insurers — at least as a matter of state law. Expect increased reliance on IFPA civil actions, rather than PIP arbitration demands, as SIU's primary enforcement vehicle going forward.

Thought Leadership

Congress Passes Financial Exploitation Prevention Act

On June 25, 2026, the House passed the Financial Exploitation Prevention Act of 2025 (“the Act”) by a vote of 414 to 2. The Act allows financial advisors and firms to delay suspicious transactions regarding the accounts of clients who are 65 or older, if they believe financial exploitation has occurred or is about to take place. With the advancement of technology and AI, the House’s overwhelming bipartisan passage of the Financial Exploitation Prevention Act represents an important step in strengthening the financial industry’s ability to combat the growing threat of elder financial exploitation. The Act recognizes what advisors have long known that financial professionals are often the first to detect suspicious behavior but have historically lacked clear legal authority to intervene before irreversible financial harm occurs. From the industry’s perspective, the bill accomplishes several important objectives, including the following: (1) Provides a practical “pause button” by allowing financial professionals to temporarily delay certain transaction requests when there is a reasonable belief that a senior or vulnerable adult is being financially exploited; (2) Empowers financial professionals to act by providing greater certainty that firms can act in good faith to protect clients without unnecessary legal risk; and (3) Strengthens investor protection without sacrificing client rights by allowing temporary delays based on a reasonable suspicion of exploitation, which is intended only to allow additional review and not to deny clients access to their money indefinitely. In sum, the Financial Exploitation Prevention Act will equip financial professionals with practical, carefully tailored tools to stop suspected financial exploitation before client assets are lost. By allowing firms to temporarily delay suspicious transactions under defined circumstances, Congress is recognizing the critical role advisors play as the first line of defense against increasingly sophisticated fraud schemes. The Act strikes an appropriate balance between protecting vulnerable investors and preserving individual financial autonomy, while reinforcing collaboration among advisors, families, and law enforcement to combat financial exploitation. The bill now awaits Senate action.

Thought Leadership

New Jersey Expands Family Leave Protections Effective July 17, 2026

On January 17, 2026, Governor Murphy signed into law legislation expanding the New Jersey Family Leave Act (NJFLA). Beginning July 17, 2026, significant amendments to the NJFLA will expand job-protected family leave to smaller businesses and more employees across the state. The new law broadens coverage by lowering the threshold for private employers from 30 employees to 15 employees, meaning many smaller businesses will now be subject to the NJFLA. Employees of state and local government agencies will continue to be covered regardless of the size of the employer. The amendments also make it easier for employees to qualify for leave. Under the revised law, an employee will be eligible after three months of employment and at least 250 hours worked during the preceding 12 months, replacing the previous requirement of 12 months of employment and 1,000 hours worked. Currently, New Jersey's Temporary Disability Insurance (TDI) and Family Leave Insurance (FLI) programs provide eligible employees with wage replacement while they are on leave but do not independently guarantee job protection. The recent amendments to the New Jersey Family Leave Act (NJFLA) expand these protections by extending job-protected leave to additional employees. Under the amended law, employees receiving TDI or FLI benefits may be entitled to return to the same position they held before taking leave, or to an equivalent position with the same seniority, status, pay, and benefits. Although the legislation also states that it does not expand or modify an employee's reinstatement rights under the NJFLA, the amendments appear to provide job protection to eligible employees receiving TDI or FLI benefits without requiring them to separately satisfy the eligibility requirements of the NJFLA or the federal Family and Medical Leave Act (FMLA). As a result, some employees may be entitled to longer periods of job-protected leave than were previously available under existing law. With these amendments, New Jersey continues to strengthen workplace protections by expanding access to job-protected family leave for eligible employees. These changes significantly expand access to job-protected family leave and may require employers to update their leave policies, employee handbooks, and HR practices. Notably, employers who were previously not required to administer NJFLA may need to amend their policies and/or create new protocols to come into compliance with the NJFLA. Failure to do so would prove costly, as the penalties for non-compliance are significant.